Clinical Trials in the USA / NCT07884175
Recruiting
Phase 4
A Study of Updated mRNA Seasonal Influenza Vaccines
NCT07884175 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Seasonal Influenza
Investigational drug(s) / intervention(s)
mRNA-1010: Sterile liquid for injection
Licensed High-Dose Seasonal Influenza Vaccine: Sterile liquid for injection
Study summary
The purpose of this study is to evaluate the immunogenicity and safety of updated strain-containing compositions of the mRNA-1010 vaccines within the current epidemiological environment.
Eligibility
Key Inclusion Criteria:
* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
* Female participants must be of non-childbearing potential.
Key Exclusion Criteria:
* Acutely ill or febrile (temperature ≥38.0 degrees Celsius (℃) \[100.4° Fahrenheit \[F\]\]) within 72 hours prior to at the Screening Visit or Day 1.
* History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic
* History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable, potentially affects participant safety, could interfere with interpretation of study results or limit the participant's participation in the study.
* History of myocarditis, pericarditis, or myopericarditis within 90 days prior to Day 1 (Baseline).
* Received corticosteroids at ≥10 mg/day of prednisone or equivalent for \>14 days in total within 90 days prior to Day 1 (Baseline) or within 28 days after Day 1.
* Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses (eg, infliximab), within 180 days prior to Day 1 (Baseline) or plans to do so during the study.
* Tested positive for influenza by US Centers for Disease Control and Prevention (CDC)-recommended testing methods within 180 days prior to Day 1.
* Received systemic immunoglobulins or blood products within 90 days prior to Day 1 (Baseline) or plans to do so during the study.
* Received any vaccine (excluding seasonal influenza vaccine) authorized or approved by local health agency within 28 days prior to Day 1 (Baseline) or plans to do so within 14 days after Day 1 (Baseline).
* Received a licensed or investigational seasonal influenza vaccine within 6 months prior to Day 1 (Baseline) or plans to do so (outside of this study) at any time during the study.
Primary outcome measure(s)
- Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay — Day 29
- Number of Participants Reaching Seroconversion at Day 29 as Measured by HAI Assay — Day 29
Seroconversion is defined as a Day 29 titer ≥1:40 if baseline is \<1:10 or a 4-fold or greater rise if baseline is ≥1:10 in anti-HA antibodies measured by HAI assay. - Number of Participants with an HAI Titer ≥1:40 at Day 29 — Day 29
- Geometric Mean Fold Rise (GMFR), as Measured by HAI Assay — Baseline to Day 29
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Arizona Clinical Trials | Tucson | Arizona | Recruiting |
| Johnson County Clin-Trials LLC (JCCT) | Lenexa | Kansas | Recruiting |
| DelRicht Research at Derby City Direct Primary Care | Louisville | Kentucky | Recruiting |
| DelRicht Research at Amy Roberts MD and Associates | Town and Country | Missouri | Recruiting |
More ModernaTX, Inc. trials in the USA
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
Active, not recruiting
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
Active, not recruiting
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07884175 on ClinicalTrials.gov ↗ ← All trials in the USA